Citius Oncology (CTOR) Total Non-Current Liabilities (2024 - 2026)
Citius Oncology (CTOR) posted quarterly Total Non-Current Liabilities of $64.9 million for Q1 2026, up 17.44% year-over-year from $55.2 million in Q1 2025, and up 27.2% quarter-over-quarter from $51.0 million in Q4 2025.
Citius Oncology (CTOR) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Total Non-Current Liabilities for 3 consecutive years, with $64.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 17.44% year-over-year to $64.9 million; the TTM figure through Mar 2026 stood at $64.9 million (up 17.44% YoY), while the FY2025 annual figure was $55.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities climbed to $64.9 million in Q1 2026 per CTOR's latest filing, from $51.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $64.9 million in Q1 2026 and bottomed at $48.6 million in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $55.7 million across 3 years, with a median of $55.4 million in 2025.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities grew 4.87% — and 2026, when it climbed 17.44%.
- Citius Oncology's Total Non-Current Liabilities stood at $48.6 million in 2024, then climbed by 4.87% to $51.0 million in 2025, then grew by 27.2% to $64.9 million in 2026.
- Business Quant data shows CTOR's Total Non-Current Liabilities at $64.9 million in Q1 2026, $51.0 million in Q4 2025, and $55.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 334.00 Mn |
| 10 | Citius Oncology | 81.99 Mn | 81.99 Mn | 1.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.87 Mn |
| Dec 31, 2025 | 51.00 Mn |
| Sep 30, 2025 | 55.52 Mn |
| Jun 30, 2025 | 58.75 Mn |
| Mar 31, 2025 | 55.24 Mn |
| Dec 31, 2024 | 48.63 Mn |